Meadows teases Trump action on immigration, China, prescription drugs

White House chief of staff Mark MeadowsMark Randall MeadowsTrump won't attend UN General Assembly in person, Meadows says McConnell focuses on confirming judicial nominees with COVID-19 talks stalled Overnight Health Care: Ex-Pence aide backs Biden over virus response | Trump's sharp words put CDC director on hot seat | Trump coronavirus adviser threatens to sue Stanford researchers MORE on Monday teased forthcoming executive action from President TrumpDonald John TrumpHR McMaster says president's policy to withdraw troops from Afghanistan is 'unwise' Cast of 'Parks and Rec' reunite for virtual town hall to address Wisconsin voters Biden says Trump should step down over coronavirus response MORE targeting immigration, China and prescription drug pricing.

"Starting this week, you’ll see executive orders, you’ll see business that actually goes forward from the Oval Office when Congress doesn’t act," Meadows told "Fox & Friends."

Meadows, who was giving his first televised interview since taking the job in March, offered few specifics on each of the orders or when they would be signed.


The president would be looking to address the United States's manufacturing relationship with China to ensure American workers are prioritized, Meadows said.

Trump was also expected to sign action on immigration. The president last month signed an executive order suspending certain work visas for the remainder of the year.

And the president is expected to focus at least one executive order on prescription drugs, Meadows said. The White House has backed congressional efforts to low drug prices, but the odds of legislation passing this year decreased in recent days.

Sen. Chuck GrassleyCharles (Chuck) Ernest GrassleySenate Republicans signal openness to working with Biden Senators offer disaster tax relief bill Trump spikes political football with return of Big Ten season MORE (R-Iowa) is preparing to introduce an updated version of a Senate bill on the issue, but no Democrats are co-sponsoring it, sinking already slim hopes that there would be a bipartisan breakthrough.